Aim: To evaluate the cardiac safety of esketamine nasal spray administered to patients with treatment-resistant depression (TRD).
Methods: Cardiovascular (CV) effects of esketamine nasal...
Objective: Phase 3 trials have demonstrated the efficacy and safety of esketamine nasal spray (ESK) plus a newly initiated oral antidepressant (AD) for treatment-resistant depression (TRD...